198 related articles for article (PubMed ID: 38548371)
1. Is LDL cholesterol associated with long-term mortality among primary prevention adults? A retrospective cohort study from a large healthcare system.
Kip KE; Diamond D; Mulukutla S; Marroquin OC
BMJ Open; 2024 Mar; 14(3):e077949. PubMed ID: 38548371
[TBL] [Abstract][Full Text] [Related]
2. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease.
Abdullah SM; Defina LF; Leonard D; Barlow CE; Radford NB; Willis BL; Rohatgi A; McGuire DK; de Lemos JA; Grundy SM; Berry JD; Khera A
Circulation; 2018 Nov; 138(21):2315-2325. PubMed ID: 30571575
[TBL] [Abstract][Full Text] [Related]
4. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
6. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
7. Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan.
Ferguson EL; Zimmerman SC; Jiang C; Choi M; Swinnerton K; Choudhary V; Meyers TJ; Hoffmann TJ; Gilsanz P; Oni-Orisan A; Whitmer RA; Risch N; Krauss RM; Schaefer CA; Glymour MM
Neurology; 2023 Nov; 101(21):e2172-e2184. PubMed ID: 37793911
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
Miles J; Scotti A; Castagna F; Kuno T; Leone PP; Coisne A; Ludwig S; Lavie CJ; Joshi PH; Latib A; Garcia MJ; Rodriguez CJ; Shapiro MD; Virani SS; Slipczuk L
Circulation; 2024 Feb; 149(6):417-426. PubMed ID: 37970713
[TBL] [Abstract][Full Text] [Related]
9. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
10. Association of Strict Versus Lenient Cholesterol Lowering with Cardiac Outcomes, Diabetes Progression and Complications, and Mortality in Patients with Diabetes Treated with Statins: Is Less More?
Odeleye V; Masarweh O; Restrepo J; Alvarez CA; Mansi IA
Drug Saf; 2023 Nov; 46(11):1105-1116. PubMed ID: 37782373
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
[TBL] [Abstract][Full Text] [Related]
12. Does Lowering Low-Density Lipoprotein Cholesterol With Statin Restore Low Risk in Middle-Aged Adults? Analysis of the Observational MESA Study.
Liu K; Wilkins JT; Colangelo LA; Lloyd-Jones DM
J Am Heart Assoc; 2021 Jun; 10(11):e019695. PubMed ID: 33998284
[TBL] [Abstract][Full Text] [Related]
13. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.
deGoma EM; Leeper NJ; Heidenreich PA
J Am Coll Cardiol; 2008 Jan; 51(1):49-55. PubMed ID: 18174036
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
Yu M; Liang C; Kong Q; Wang Y; Li M
Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
[TBL] [Abstract][Full Text] [Related]
16. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk.
Brown CJ; Chang LS; Hosomura N; Malmasi S; Morrison F; Shubina M; Lan Z; Turchin A
JAMA Netw Open; 2023 Feb; 6(2):e231047. PubMed ID: 36853604
[TBL] [Abstract][Full Text] [Related]
18. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
